Department of Bioengineering, George Mason University, Fairfax, VA, 22030, USA.
National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA, 20110, USA.
Commun Biol. 2023 Mar 23;6(1):308. doi: 10.1038/s42003-023-04689-2.
Effective and safe vaccines are invaluable tools in the arsenal to fight infectious diseases. The rapid spreading of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 pandemic has highlighted the need to develop methods for rapid and efficient vaccine development. DNA origami nanoparticles (DNA-NPs) presenting multiple antigens in prescribed nanoscale patterns have recently emerged as a safe, efficient, and easily scalable alternative for rational design of vaccines. Here, we are leveraging the unique properties of these DNA-NPs and demonstrate that precisely patterning ten copies of a reconstituted trimer of the receptor binding domain (RBD) of SARS-CoV-2 along with CpG adjuvants on the DNA-NPs is able to elicit a robust protective immunity against SARS-CoV-2 in a mouse model. Our results demonstrate the potential of our DNA-NP-based approach for developing safe and effective nanovaccines against infectious diseases with prolonged antibody response and effective protection in the context of a viral challenge.
有效且安全的疫苗是对抗传染病的有力武器。导致 2019 年冠状病毒病大流行的严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)迅速传播,凸显出需要开发快速有效的疫苗开发方法。呈现预定纳米级图案的多种抗原的 DNA 折纸纳米颗粒(DNA-NPs)最近已成为合理设计疫苗的安全、高效且易于扩展的替代方法。在这里,我们利用这些 DNA-NPs 的独特性质,并证明将 SARS-CoV-2 的受体结合域(RBD)的重构三聚体的十个拷贝与 CpG 佐剂精确地上图案化在 DNA-NPs 上,能够在小鼠模型中引发针对 SARS-CoV-2 的强大保护免疫。我们的结果表明,我们的基于 DNA-NP 的方法具有开发针对传染病的安全有效的纳米疫苗的潜力,该疫苗具有延长的抗体反应和在病毒挑战下的有效保护。